Acute myeloid leukemia (AML) predominantly affects older adults, with two-thirds of cases diagnosed after the age of 60 [1]. In this population, therapeutic options have significantly expanded: intensive chemotherapy (ICT) remains the standard for fit patients, whereas venetoclax (Ven)–based low-intensity therapies (LIT) are increasingly used.
Nicolas Duployez
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Nicolas
Contact Nicolas, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack